Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

One pill a day? HIV study tests simpler combo

NCT ID NCT00196599

Disease control Sponsor: ANRS, Emerging Infectious Diseases Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a once-daily combination of three HIV drugs (FTC, ddI, efavirenz) in 39 adults who had never taken HIV medication before. The goal was to see if this simpler, once-a-day pill routine worked well and had fewer side effects than older treatments. Participants had HIV and a CD4 count above 100, but were otherwise healthy. The study measured how well the drugs controlled the virus and tracked safety and adherence.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

39 people

Start date

Feb 1999

Completion date

Sep 2004

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * HIV infection * Antiretroviral naive * CD4 cell count over 100/mm3 * Plasma HIV RNA load over 5,000 copies/mL * Signed written informed consent Exclusion Criteria: * Hepatitis B infection * Pregnancy * Alcool abuse * Acute infection, past neurological or pancreatic disease, biological abnormalities * Chemotherapy or immunotherapy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Antiretroviral naive are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Antiretroviral naive HIV infections

Contacts and locations

Locations

  • Service de Maladies Infectieuses, Hôpital Saint-Louis

    Paris, 75475, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.